Business Context and Reporting Period
This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on August 21, 2018. The filing reports the entry into a material definitive agreement to facilitate an "at-the-market" equity offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Controlled Equity Offering SM Sales Agreement.
- Counterparty: Cantor Fitzgerald & Co. (acting as sales agent).
- Maximum Offering Size: Up to $25,000,000 in aggregate offering price.
- Compensation: The Company will pay the Agent a commission of 3.0% of the aggregate sales price per share sold.
- Registration: Shares will be offered pursuant to a shelf registration statement on Form S-3 (Registration No. 333-218517).
- Financial Performance: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
Material Changes and Agreements
The primary material change is the authorization to sell common stock through an agent at prevailing market prices. The Company is not obligated to sell, and the Agent is not obligated to buy or sell any shares. No assurance is given regarding the price, amount, or timing of potential sales.
Guidance, Risks, and Contingencies
- Warrant Waivers: Holders of outstanding warrants issued in December 2015 agreed to irrevocably waive their preemptive rights regarding this offering.
- Amendments to Purchase Agreements: Holders of shares/warrants under the April 2017 Purchase Agreement amended their agreements to exclude "at-the-market" transactions from notice and participation rights.
- Risks: The filing explicitly states that no assurance can be given that the Company will sell any shares, nor the specific terms (price, amount, dates) if sales occur.
Investor Verification Checklist
- Verify the current share price and trading volume on the Nasdaq Capital Market to assess the potential dilution impact of a $25 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination clauses or volume caps not detailed in the summary.
- Confirm the outstanding number of December 2015 warrants and 2017 Purchase Agreement instruments to understand the scope of the waivers.
- Check subsequent filings (e.g., 10-Q or 10-K) for actual sales executed under this agreement and the resulting cash proceeds.